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Abstract
Background: Sulphadoxine-pyrimethamine (SP), an antifolate, was replaced by artemether-lumefantrine as the first-line
malaria drug treatment in Kenya in 2004 due to the wide spread of resistance. However, SP still remains the
recommended drug for intermittent preventive treatment in pregnant women and infants (IPTP/I)o w i n gt oi t ss a f e t y
profile. This study assessed the prevalence of mutations in dihydrofolate reductase (Pfdhfr)a n ddihydropteroate synthase
(Pfdhps) genes associated with SP resistance in samples collected in Kenya between 2008 and 2012.
Methods: Field isolates collected from Kisumu, Kisii, Kericho and Malindi district hospitals were assessed for genetic
polymorphism at various loci within Pfdhfr and Pfdhps genes by sequencing.
Results: Among the Pfdhfr mutations, codons N51I,C 5 9 R,S 1 0 8 N showed highest prevalence in all the field sites at 95.5%,
84.1% and 98.6% respectively. Pfdhfr S108N prevalence was highest in Kisii at 100%. A temporal trend analysis showed
steady prevalence of mutations over time except for codon Pfdhps 581 which showed an increase in mixed genotypes.
Triple Pfdhfr N51I/C59R/S108N and double Pfdhps A437G/K 5 4 0 E had high prevalence rates of 86.6% and 87.9%
respectively. The Pfdhfr/Pfdhps quintuple, N51I/C59R/S108N/A437G/K540E m u t a n tw h i c hh a sb e e ns h o w nt ob et h em o s t
clinically relevant marker for SP resistance was observed in 75.7% of the samples.
Conclusion: SP resistance is still persistently hi g hi nw e s t e r nK e n y a ,w h i c hi sl i k e l yd ue to fixation of key mutations in the
Pfdhfr and Pfdhps genes as well as drug pressure from other antifolate drugs being used for the treatment of malaria and
other infections. In addition, there is emergence and increasing prevalence of new mutations in Kenyan parasite
population. Since SP is used for IPTP/I, molecular surveillance and in vitro susceptibility assays must be sustained to provide
information on the emergence and spread of SP resistance.
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Sulphadoxine-pyrimethamine (SP) has been widely used as
first-line treatment for uncomplicated falciparum malaria in
many parts of the world including sub-Saharan Africa. It is
used alone or in combination with other anti-malarials
which has been effective until recently because of high
levels of resistance [1,2]. SP has been replaced with other
anti-malarials as the first-line treatment in most of sub-
Saharan Africa including Kenya [3]. However, SP is still
used as intermittent preventive treatment of malaria in
pregnancy (IPTp) in sub-Saharan Africa [4]. It was recently
recommended for use as intermittent preventive treatment
of malaria in infants (IPTi) by the World Health
Organization (WHO) in areas with low SP resistance [5].
There has been continued increase in SP resistance albeit
being replaced as the first-line treatment [6], which is a
major public health concern especially in sub-Saharan
Africa [7].
SP resistance is conferred by mutations in Plasmodium
falciparum dihydrofolate reductase (Pfdhfr)a n dP. falcip-
arum dihydropteroate synthase (Pfdhps) genes [8,9], whose
enzymes are target for pyrimethamine and sulphadoxine re-
spectively. Pfdhfr S108N mutation has been linked to pyri-
methamine resistance. Additional point mutations A16V,
N51I and C59R lead to increased resistance [10,11]. High
grade pyrimethamine resistance is linked to the occurrence
of the I164L mutation [12] which has been observed to-
gether with the Pfdhfr gene triple N51I/C59R/S108N mu-
t a n ti nS o u t h e a s tA s i aa n dt h eA m e r i c a s[ 1 2 , 1 3 ] .Pfdhfr
I164L mutation, which is shown to cause rapid spread of
antifolate resistance, has been observed in the western parts
of Kenya [7,14]. Pfdhps A437G mutation is mainly associ-
ated with sulphadoxine resistance with increased resistance
conferred in the presence of additional point mutations
S436A/F/H, A581G,K 5 4 0 E and A613S/T [9,15]. Differing
extents of anti-malarial drug resistance to SP are subject to
the varying numbers and combinations of mutations
present in the Pfdhfr and Pfdhps genes [11,16]. Primarily,
the Pfdhfr/Pfdhps N51I,C 5 9 R, S108N/A437G, K540E
quintuple mutation has strongly been associated with clin-
ical SP treatment failure [11].
A recent meta-analysis of the frequencies of Pfdhfr and
Pfdhps mutant genotype in African P. falciparum parasite
populations revealed high prevalence of mutant genotypes
along the Kenya-Tanzania border and Malawi [6]. To assess
the prevalence of mutations in Pfdhfr and Pfdhps genes and
the impact of introducing SP as the first-line treatment in
Kenya, two studies were conducted. A baseline study was
conducted in 1999-2000 [17] and the follow-up study in
2003-2005 [18]. The baseline study coincided with the im-
plementation of SP as the first-line treatment whereas the
follow-up study coincided with transition to artemether-
lumefantrine (AL) as the first-line treatment. The preva-
lence of isolates containing the quintuple mutant genotype
(Pfdhfr N51I/C59R/S108N/ Pfdhps A437G/K540E)r o s e
from 21% in the baseline study to 53% in the follow-up
study (P< 0.001) [17,18]. The Pfdhfr I164L mutation was
not present in either of the study. Interestingly, a study that
analyzed prevalence of the I164L mutation in sample iso-
lates collected in the same region in 2002-2008 and 2008-
2009 reported a prevalence of 0.6% and 0.8% respectively
[19]. There were no mutations at Pfdhps codons 581 and
613 at the baseline study but 85% and 61% of the sample
isolates in the follow-up study carried mutations at these
two codons, respectively [19].
Since SP remains widely used as IPTp and is a possible
ACT partner drug as well as IPTi candidate, there is
heightened recognition underlying the need to track the
prevalence of mutations associated with SP resistance.
This study presents the prevalence and trend of muta-
tions in Pfdhfr and Pfdhps genes in sample isolates col-
lected from 4 different sites in Kenya between 2008 and
2012.
Methods
Study sites and sampling collection
This study was conducted after approval by the Kenya
Medical Research Institute (KEMRI) and Walter Reed
Army Institute of Research (WRAIR) institutional review
boards (protocol numbers: KEMRI 1330, WRAIR 1384;
Epidemiology of malaria drug sensitivity pattern). The
samples used in this study were collected at district hos-
pitals from four regions in Kenya; viz Kisumu District
Hospital (KDH), Kisii District Hospital (KSI), Kericho
District Hospital (KCH) and Malindi District Hospital
(MDH) between the years 2008 and 2012. Kisumu is lo-
cated in the western region of the country at the shores
of Lake Victoria. This is a lowland region with holoen-
demic malaria. Kisii and Kericho are both highland areas
also in the western Kenya regions which experiences
hypoendemic malaria. Malindi is at the Kenyan coastal
lowland region, but has different malaria episodes from
Kisumu, which is also at lowland in the western Kenya
region [20,21].
Consenting patients aged six months and above, testing
positive for uncomplicated P. falciparum malaria by rapid
diagnostic test (RDT; Parascreen® (Pan/Pf), Zephyr Bio-
medicals, Verna Goa, India) were allowed to participate in
the study. Briefly, 2-3 ml of whole blood was collected from
the participants. FTA filter paper (Whatman Inc., Bound
Brook, New Jersey, USA) was used to collect 3 blood spots
of about 100 μl each for DNA extraction.
Genotypic analysis for Pfdhfr and Pfdhps
The DNA was extracted from the FTA filter papers using
the QIAamp DNA mini kit; Qiagen protocol (Qiagen,
Valencia, CA). Screening for mutations associated with
antifolate resistance at codons 16, 50, 51, 59, 108, and 164
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of the Pfdhps gene was performed by nested PCR as previ-
ously described [22,23]. After successfully amplifying the
target regions, the isolates were purified using Exosap-it®
(Affymetrix, Santa Clara, CA) as per the manufacturer’s
protocol. Sequencing of the target regions was done on the
3500 xL ABI Genetic analyzer using version 3.1 of the big
dye terminator method (Applied Biosystems, Foster City,
CA). Contig assembly of the generated sequences was per-
formed using DNA Baser version 3× and the sequences
aligned and analysed using BioEdit version 7.1.3.0. All se-
quences were compared against the Pfdhfr (Accession
Number; XM_001351443) and Pfdhps (Accession Number;
XM_001349382) 3D7 reference sequence published at the
NCBI database.
Statistical analysis
Categorical data consisting of genotype polymorphisms
within Pfdhfr, Pfdhps genes was analyzed as proportions
showing rates of frequency. The differences in frequencies
of point mutations in the Pfdhfr, Pfdhps genes and the com-
bined Pfdhfr/Pfdhps genes within and between regions were
determined by the Chi-square test. For evaluating trends,
the annual frequencies of polymorphisms of individual co-
dons, during the study period were compared. Further,
comparison of genotype frequencies of 2003 to 2005 and
2008 to 2012 study periods was performed by Chi-square
test. Yates’ correction was applied for the chi-square value,
resulting in corrected P values. All statistical analyses were
performed at the 5% significance level and the correspond-
ing 95% Confidence Interval (CI). Prism 4.0 software
(Graph pad Software, San Diego, California, USA) was used
for analyses.
Results
Prevalence of SNPs in Pfdhfr and Pfdhps genes
A total of 869 archival field isolates collected from KDH,
KSI, KCH and MDH between 2008 and 2012 were included
in the study of which 822 were successfully sequenced.
Eleven SNPs were genotyped, six loci in the Pfdhfr gene
and five loci in Pfdhps gene as shown in the methods sec-
tion. There were no mutations in Pfdhfr gene at codons 16
and 50 as well as Pfdhps gene at codon 613. These codons
are excluded from any further analysis. Using the criteria
that was recently described by Iriemenam et al.[ 1 9 ] ,S N P s
were designated as pure (which contains only either wild
type or mutant strains) or as mixed (which contained both
wild type and mutant alleles based on presence of two
major peaks of the chromatograms). Figure 1 shows the
overall prevalence of genotypes at each codon. The preva-
lence of mutation at Pfdhfr codons 51, 59 and 108 was
95.5%, 84.1% and 98.6% respectively. There were five (0.8%)
sample isolates that carried the pure mutant and 2 (0.3%)
samples that had the mixed SNP at Pfdhfr codon 164. The
prevalence of mutation at Pfdhps codons 436, 437, 540 and
581 was 0.2%, 95.7%, 86.8%, and 0.8%.
Prevalence of mutant alleles in Pfdhfr and Pfdhps genes
per study site
Table 1 shows the prevalence of Pfdhfr and Pfdhps SNPs
per study site for the entire period which isolates were
collected. SNPs are classified as wild type, mutant or
mixed. The prevalence of mutant allele at Pfdhfr codon
108 was highest, with KSI and KDH having 100% and
99.6% of the sample isolates carrying the mutant allele
respectively. MDH had the lowest prevalence of muta-
tions in Pfdhfr gene at codons 51, 59 and 108 compared
to the other sites (P =0.0052, 0.0002 and 0.0066) re-
spectively. Mutation at Pfdhfr codon 164 was present
only in samples collected in KDH and KSI. There were
five sample isolates which carried the pure mutant (three
from KDH and two from KSI), and two sample isolates,
one from each site that carried the mixed SNP genotype.
In Pfdhps gene, the prevalence of mutant allele at Pfdhps
codon 437 was highest, with KDH and KSI having 98.1%
and 97.9% of the sample isolates carrying the mutant al-
lele respectively. Mutant and mixed SNPs at Pfdhps
codon 581 was present in sample isolates collected in
KDH, KSI and KCH. MDH site had the lowest preva-
lence of mutant alleles at codons 437 and 540 compared
to the other sites.
Temporal trends of SNPs in Pfdhfr and Pfdhps genes
Additional file 1 shows the temporal trends of mutations
in Pfdhfr and Pfdhps genes of samples collected from all
the four sites. Samples collected from KDH and KCH
displayed steady prevalence over time at all codons ex-
cept for codon 581 in KDH which the prevalence of
mixed genotype increased from 1.2% in 2009 to 15.6% in
2012. However, MDH and to lesser extent KCH showed
changing temporal trends. At MDH, samples collected
in 2011 had lower prevalence of mutation in Pfdhfr co-
dons 51, 108 and Pfdhps codon 437 compared to sam-
ples collected in 2010 and 2012. Chi-square analysis
showed that the prevalence of Pfdhfr codon 108 and
Pfdhps codon 437 mutant genotypes were significantly
different (P =0.016 and 0.039) respectively. Although it
did not reach statistical significance, there was a down-
ward trend of the prevalence of mutation at codon 59
and 540 (P =0.875 and 0.5146), respectively, for samples
collected in KCH and MDH.
Prevalence of Pfdhfr and Pfdhps genotypes
Prevalence of Pfdhfr and Pfdhps genotypes was based on
criteria that were originally described by Kublin et al.
[11] and recently by Iriemenam et al. [19]. Genotype
analysis was done only on those samples that were suc-
cessfully analysed at all loci. Mixed genotypes containing
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tant (single) alleles for analysis. Pfdhfr genotypes were
based on mutations at codons 51, 59, and 108 which
were classified as wild type, single, double, and triple.
Pfdhps genotypes were based on mutations at codons
437 and 540 which were classified as wild type, single,
and double. Combined Pfdhfr (51, 59, and 108) and
Pfdhps (437, 540) genotypes were defined as wildtype,
Table 1 Prevalence of single nucleotide polymorphism in Pfdhfr and Pfdhps per site
DHFR prevalence per site DHPS prevalence per site
CODON 16 50 51 59 108 164 S436A/F/H 437 540 581 613
% (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n)
KDH
WILD 100 (266) 100 (289) 1.4 (4) 3.5 (10) 0.3 (1) 98.7 (302) 100 (256) 1.5 (4) 7.5 (21) 97.2 (273) 100 (284)
MUTANT 0 (0) 0 (0) 96.9 (279) 92.7 (267) 99.6 (296) 1 (3) 0 (0) 98.1 (264) 91.1 (256) 0.4 (1) 0 (0)
MIXED 0 (0) 0 (0) 1.7 (5) 3.8 (11) 0 (0) 0.3 (1) 0.4 (1) 0.4 (1) 1.4 (4) 2.5 (7) 0 (0)
KSI
WILD 100 (152) 100 (155) 1.3 (2) 11.0 (17) 0 (0) 98.1 (155) 100 (87) 1.1 (1) 9.9 (14) 96.7 (146) 100 (117)
MUTANT 0 (0) 0 (0) 96.9 (152) 82.5 (127) 100 (156) 1.32 (2) 0 (0) 97.9 (91) 89.4 (126) 2.0 (3) 0 (0)
MIXED 0 (0) 0 (0) 1.9 (3) 6.5 (10) 0 (0) 0.6 (1) 0 (0) 1.1 (1) 0.7 (1) 1.3 (2) 0 (0)
KCH
WILD 100 (93) 100 (93) 2.2 (2) 7.7 (6) 2.1 (2) 100 (93) 98.9 (89) 2.2 (2) 3.8 (4) 98.1 (102) 100 (104)
MUTANT 0 (0) 0 (0) 97.9 (91) 73.1 (57) 97.9 (92) 0 (0) 0 (0) 96.7 (87) 90.4 (94) 1.0 (1) 0 (0)
MIXED 0 (0) 0 (0) 0 (0) 19.2 (15) 0 (0) 0 (0) 1.1 (1) 1.1 (1) 5.8 (6) 1.0 (1) 0 (0)
MDH
WILD 100 (99) 100 (103) 10.7 (11) 24.3 (25) 5.8 (6) 100 (103) 98.9 (98) 13.2 (14) 11.9 (12) 100 (104) 100 (107)
MUTANT 0 (0) 0 (0) 87.4 (90) 70.9 (73) 94.2 (97) 0 (0) 1.0 (1) 86.8 (92) 86.1 (87) 0 (0) 0 (0)
MIXED 0 (0) 0 (0) 1.9 (2) 4.9 (5) 0 (0) 0 (0) 0 (0) 0 (0) 2.0 (2) 0 (0) 0 (0)
Prevalence of Pfdhfr and Pfdhps wildtype, mutant and mixed genotypes per study site for the entire period was calculated as a percentage of the total number of
samples successfully analysed over the study period per codon per the specific site.
Figure 1 Prevalence of single nucleotide polymorphism in Pfdhfr and Pfdhps. The overall prevalence of genotypes at each codon on the
Pfdhfr and Pfdhps genes were determined over the 5 year period, calculated as a percentage of the total number of samples successfully
analyzed over the study period per codon.
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ple genotype represented infections in which all the five
mutations were present. Additional combinations which
contained mutation at Pfdhfr codon 164, Pfdhps codons
436 and 581 were genotyped as well.
Additional file 2 shows the prevalence of genotypes in
Pfdhfr or Pfdhps genes. In Pfdhfr gene, triple mutant
(N51I/C59R/S108N) was the most prevalent at 86.6% in
all sites combined whereas single mutant (C59R), double
mutant (N51I/C59R) and the quadruple mutant (N51I/
C59R/S108N/I164L) were the least prevalent at 0.26%
each. When broken further per site, the triple mutant
was most prevalent in KDH at 93.7% whereas least
prevalent in MDH at 67.9%. There was no genotype ob-
served which contained Pfdhfr N51I single mutant. In
the Pfdhps gene, double mutant (A437G/K540E) was the
most prevalent at 87.9% whereas single mutant (S436A)
was the least prevalent at 0.26% (one sample). Interest-
ingly, two of the four samples in triple mutant 436/437/
540 carried S436F and S436H amino acid mutation and
not the S436A which has been shown to be more preva-
lent mutation [19] . These mutations occurred either as
a triple S436F/A437G/K540E or S436H/A437G/K540E
mutations. Of note is prevalence of A581G mutant
which has been rare in the region, but has been seen to
emerge in recent years [19]. The A581G mutant ap-
peared as a genotype in combination with the A437G
mutation in 0.78% of the isolates analysed. It was also
observed as a triple A437G/K540E/A581G mutant geno-
type in 1.6% of the samples. Interestingly, A581G mutant
was not observed as a single mutant, but appeared in
the presence of other mutations on the gene.
Additional file 3 shows the prevalence of genotypes in
combined Pfdhfr and Pfdhps genes. In all the sites, the
quintuple mutant (Pfdhfr/Pfdhps N51I,C59R,S108N/A43
7G,K540E) was the most prevalent at 75.71% whereas the
least prevalent was quadruple mutant (Pfdhfr/Pfdhps N51I,
C59R,S108N/S436A)a n ds e x t u p l em u t a n t( Pfdhfr/Pfdhps
N51I,C59R,S108N,I 1 6 4 L/A437G,K540E)a t0 . 2 6 % .W h e n
broken down per site, KCH had the highest prevalence of
the quintuple mutant at 89.6% whereas MDH was the low-
e s ta t5 4 . 3 % .
Temporal trends of genotypes in Pfdhfr and Pfdhps genes
Additional file 4 shows percent temporal prevalence of
genotypes from 2008-2012. In Pfdhfr gene, the wildtype
of the genotype analysed is N51,C59,S108,I164 (NCSI)
and in the Pfdhps gene, the wildtype of the genotype
analysed is S436,A437,K540,A581 (SAKA). For Pfdhfr
gene, the prevalence of wildtype genotype increased
slightly from 2008 to 2011, but was not present in 2012.
The IRNI genotype (triple mutant, 51I,59R,108 N) was
the most prevalent but decreased from 92.5% in 2008 to
72.3% in 2012. For Pfdhps gene, the prevalence of the
wildtype genotype was not steady overtime. The SGEA
genotype (double mutant, 437G, 540E) was the most
prevalent. However, unlike the Pfdhfr IRNI genotype
which declined over time, the Pfdhps SGEA genotype
remained relatively stable over time.
Discussion
The Pfdhfr/Pfdhps N51I, C59R, S108N/A437G, K540E
quintuple mutant genotype is strongly associated with
clinical SP treatment failure [11]. Using sample isolates
collected from general patient population, quintuple mu-
tant genotype was shown to be the most prevalent com-
bined genotype at 75.7%. When further broken down
per site, KCH and KDH had the highest prevalence at
89.6% and 80.6%, respectively whereas MDH had the
lowest prevalence at 54.3% (see Additional file 3). In
other studies conducted in Kenya using sample isolates
collected in Kisumu, Iriemenam et al. [19] and Spalding
et al. [18] showed prevalence of the quintuple mutant
genotype to be at 88% and 53% respectively. The differ-
ence in prevalence can be explained by the period and
patient population which sample isolates were collected
from. Iriemenam et al. study used sample isolates col-
lected in 2008-2009 from pregnant patient population
whereas Spalding et al. used general patient population
sample isolates collected in 2003-2005. In the current
study, the prevalence of the quintuple mutant phenotype
is similar to that from Iriemenam et al. study most likely
because the samples were collected around the same
period. The small difference seen can be attributed to
the difference in patient population that sample isolates
were collected from and is also reflective of the malaria
attack rates found in those locations. The attack rate has
been significantly lower at the coast over the last five
years, due mostly to the use of bed nets and other envir-
onmental controls [21].
Although 2003-2005 marked the period which SP was
discontinued and AL introduced as first-line treatment for
malaria, the prevalence of Pfdhfr/Pfdhps N51I,C 5 9 R, S10
8N/A437G, K540E quintuple mutant genotype which is
strongly associated with clinical SP treatment failure con-
tinued to increase at an alarming rate during this period.
Iriemenam et al. and Spalding et al. studies observed the
prevalence of the quintuple mutant genotype increase from
7% and 21% in sample isolates collected in 1996-2000 and
1999-2000 to 88% and 53% in samples collected in 2008-
2009 and 2003-2005 respectively. In the current study, the
prevalence of quintuple mutant genotype in KDH (western
Kenya) was 80.6%. These studies indicate that there is a fix-
ation of the sulphadoxine-pyrimethamine resistant alleles in
parasite population from western Kenya. Such fixation has
also been observed in Southeast Asia [23], contrary to what
has been reported in the Amazon region of Peru where
a decline in sulphadoxine-pyrimethamine-resistant alleles
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ation of the resistance alleles have been attributed to para-
sites that may have acquired additional compensatory
mutations [25]. The fitness cost imposed by the mutations
does not impact the parasite and the parasite popula-
tions are fixed for resistance with no competing sensi-
tive parasite. There is also the probable presence of
additional selective pressure from antifolate drugs such
as cotrimoxazole (trimethoprim-sulphamethoxazole)
[26,27]. In addition to widespread use of cotrimoxazole,
SP continues to be widely available at the local pharma-
cies (chemists) with self-report SP use still high regard-
less of AL being the recommended first-line malaria
treatment in Kenya. Experimental or epidemiological
evidence however will be required to show an associ-
ation between cotrimoxazole and the occurrence of
Pfdhps/Pfdhfr mutations in P. falciparum. In a recently
concluded randomized trial, one group of HIV-infected
individuals discontinued cotrimoxazole prophylaxis for
12 months whereas the second group continued with
cotrimoxazole prophylaxis (unpublished data, personal
communication with Dr. Christina Polyak). Comparison
of the prevalence of malaria and mutations in Pfdhps/
Pfdhfr genes in the group that discontinued cotrimoxa-
zole prophylaxis to the group that continued will pro-
vide evidence of any association between cotrimoxazole
and the occurrence of Pfdhps/Pfdhfr mutations in P. fal-
ciparum. Other factors such as host immunity and
transmission intensity might attribute to the fixation of
Pfdhps/Pfdhfr mutant alleles in parasites in western
Kenya [19].
Mutations at Pfdhps codon 581 and Pfdhfr codon 164
have been linked to high rate of therapeutic failures in
Southeast Asia, South America [23,28] and more recently
in Africa [29-31]. Recent studies have shown emergence
and increase of the triple mutant allele (A437G/K540E/
A581G) in Tanzania [29,32]. Alifrangis et al. [32] showed
t h a tt h ep r e v a l e n c eo fm u t a t i o na tPfdhps codon 581 in-
creased significantly from 12% in 2003 to 56% in 2007,
r e s u l t i n gi na ni n c r e a s ei nt h et r i p l em u t a n tPfdhps haplo-
type (A437G/K540E/A581G) from 8% to 32%. In studies
conducted in Kenya, Iriemenam et al. [19] and Spalding
et al. [18] found the prevalence of triple mutant Pfdhps
h a p l o t y p et ob e5 . 3 %a n d1 5 %r e s p e c t i v e l yw h e r e a si nt h i s
study, the prevalence was 1.6% (see Additional file 2). Sam-
ple isolates from Iriemenam et al. study and the current
study were collected around the same period (2008-2009
vs. 2008-2012) and showed similar prevalence of the triple
mutant Pfdhps haplotype. However, sample isolates from
Spalding et al. study collected in 2003-2005 showed signifi-
cantly high prevalence of mutations at Pfdhps codon 581
(85%), only three years after mutations at the Pfdhps codon
did not exist [17]. This is unexpected since Iriemenam
et al. study and the current study, which used sample iso-
lates collected at later time period showed lower prevalence
o ft h et r i p l em u t a n tPfdhps haplotype (A437G/K540E/
A581G), yet prevalence of this mutation has been on a
steady increase during the SP treatment period [19]. How-
e v e rt h ep r e v a l e n c eo ft h et r i p l em u t a n tPfdhps haplotype
from Spalding et al. study is similar to that seen in Tanzania
[32]. Mutation at Pfdhfr codon 164 remains low. The study
done using samples collected from western Kenya between
1992 and1999 by McCollum et al. [33] indicated very low
prevalence of Pfdhfr wild type alleles while majority had
double Pfdhfr 51/108, 59/108 and Pfdhps 437/540 muta-
tions (50%, 27% and 57% respectively). Pfdhps wild type al-
leles were relatively high at 34% at that period. This was a
period before SP was the first line antimalarial treatment
and indicated initial development of resistant traits in the
population.
This is the first study which compares prevalence of
drug resistance mutant genotypes in Pfdhfr and Pfdhps
Table 2 P values indicating significance in statistical differences, P= 0.05
Western Kenya (n=306) Western Kenya (n=306) vs MDH (n= 81)
Pfdhfr codons
16 1.0000 1.0000
50 1.0000 1.0000
51 0.7762 0.0007
59 0.0904 <0.0001
108 0.3642 0.0240
164 0.3629 0.2571
Pfdhps codons
436 0.3629 0.2964
437 0.4068 <0.0001
540 0.2323 0.2259
581 0.7092 0.2638
613 1.0000 1.0000
P value of the mutant prevalence of each codon was calculated. Comparison was done in samples from western Kenya study sites (KDH, KSI, and KCH) and also
between the western Kenya sites verses the coastal study site (MDH) to determine statistical differences in prevalence between the two geographical regions.
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coastal regions of Kenya. Sample isolates collected from
Malindi (MDH) showed significant difference in preva-
lence of drug resistance alleles in Pfdhfr and Pfdhps
genes compared to sample isolates collected from west-
ern Kenya (Table 2). Interestingly, mutation in Pfdhfr
codon 51 and 108 as well as Pfdhps codon 437 decreased
in 2011 compared to 2010, but increased in 2012. Muta-
tion in Pfdhps codon 540 remained the same in 2010
and 2011, but increased significantly in 2012 (P =
0.0196). To the contrarily, Pfdhfr codon 59 significantly
decreased from 2010 to 2012 (P=0.0064). The preva-
lence and the temporal trends of mutations in Pfdhfr
and Pfdhps genes in Malindi represent interesting dy-
namics which could be driven by a number of factors in-
cluding natural phenomenon which is yet to be
determined. The prevalence of malaria is generally on a
steady decline in the Kenyan coast (personal communi-
cation with Dr. Kevin Marsh) [34] which might result to
changes in the immunity of the population in this re-
gion. Also, the dip in prevalence seen in 2011 might be
due to environmental conditions such as weather pat-
terns which can impact transmission intensity hence the
prevalence of drug resistance genotype. Interesting how-
ever, mutation at Pfdhfr codon 59 showed a steady de-
cline from 2010 to 2012. Further studies are required to
further elucidate the dynamics of mutations in Pfdhfr
and Pfdhps genes in Kenyan coast.
Conclusion
T h ed a t ap r e s e n t e di nt h i ss t u d yc o n f i r m st h ef i x a t i o no f
key mutations in the Pfdhfr and Pfdhps genes conferring re-
sistance to SP. It also shows that there is emergence and in-
creasing prevalence of new mutations in the Kenyan
parasite population. The adoption of SP in IPTp might only
be playing a minor role in these observations. The main
contributors of the antifolate drug pressure are likely to be
over the counter SP self-medication and the use of cotri-
moxazole in management of HIV patients. Apart from dis-
couraging SP use for symptomatic malaria treatment,
further evaluation should be undertaken to show effect of
the highly prevalent Pfdhfr/Pfdhps quintuple mutant com-
bining with the emerging Pfdhfr 164 and/or the Pfdhps 581
on the efficacy of IPTp or IPTi. A continuous molecular
surveillance accompanied by in vitro susceptibility testing
will provide valuable information urgently needed to con-
trol or reduce spread of SP resistance.
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